Drugs moving into the clinic: 37

By Mike Nagle

- Last updated on GMT

The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.

Sponsor Name Indication Mechanism
Bionomics BNC105 Oncology Vascular Disruption Agent
Brane Discovery BND-11624 CNS - neuropathic pain Novel pyrrolidinone derivative. Target undisclosed but same class as nefiracetam and levetiracetam, the latter of which targets synaptic vesicle protein SV2A
MedImmune CAM-3001 Rheumatoid arthritis Human monoclonal antibody (MAb) targeting the alpha subunit of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR)
Santen Pharmaceutical DE-102 macular edema Steroidal treatment using Oakwood's Chroniject sustained release delivery technology.
University of Pennsylvania & University of Florida undisclosed Blindness (hereditary) - Leber congenital amaurosis type 2 (LCA2) RPE65 gene therapy

Related topics: Preclinical Research

Related news

Show more